Cite
HARVARD Citation
Kaufman, H. et al. (n.d.). 3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704). European journal of cancer. pp. S674-. [Online].